Abstract
Background
GENetics of mOyaMoyA (GEN-O-MA) project is a multicenter observational study implemented in Italy aimed at creating a network of centers involved in moyamoya angiopathy (MA) care and research and at collecting a large series and bio-repository of MA patients, finally aimed at describing the disease phenotype and clinical course as well as at identifying biological or cellular markers for disease progression. The present paper resumes the most important study methodological issues and preliminary results.
Methods
Nineteen centers are participating to the study. Patients with both bilateral and unilateral radiologically defined MA are included in the study. For each patient, detailed demographic and clinical as well as neuroimaging data are being collected. When available, biological samples (blood, DNA, CSF, middle cerebral artery samples) are being also collected for biological and cellular studies.
Results
Ninety-eight patients (age of onset mean ± SD 35.5 ± 19.6 years; 68.4% females) have been collected so far. 65.3% of patients presented ischemic (50%) and haemorrhagic (15.3%) stroke. A higher female predominance concomitantly with a similar age of onset and clinical features to what was reported in previous studies on Western patients has been confirmed.
Conclusion
An accurate and detailed clinical and neuroimaging classification represents the best strategy to provide the characterization of the disease phenotype and clinical course. The collection of a large number of biological samples will permit the identification of biological markers and genetic factors associated with the disease susceptibility in Italy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bersano A, Guey S, Bedini G, Nava S, Hervé D, Vajkoczy P, Tatlisumak T, Sareela M, van der Zwan A, Klijn CJ, Braun KP, Kronenburg A, Acerbi F, Brown MM, Calviere L, Cordonnier C, Henon H, Thines L, Khan N, Czabanka M, Kraemer M, Simister R, Prontera P, Tournier-Lasserve E, Parati E, European Moyamoya Initiative (2016) Research progresses in understanding the pathophysiology of moyamoya disease. Cerebrovasc Dis 41:105–118
Bedini G, Blecharz KG, Nava S, Vajkoczy P, Alessandri G, Ranieri M, Acerbi F, Ferroli P, Riva D, Esposito S, Pantaleoni C, Nardocci N, Zibordi F, Ciceri E, Parati EA, Bersano A (2016) Vasculogenic and angiogenic pathways in moyamoya disease. Curr Med Chem 23:315–345
Kleinloog R, Regli L, Rinkel GJ, Klijn CJ (2012) Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review. J Neurol Neurosurg Psychiatry 83:531–536
Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG (1997) Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg 99(Suppl 2):S58–S60
Bao XY, Duan L, Li DS, Yang WZ, Sun WJ, Zhang ZS, Zong R, Han C (2012) Clinical features, surgical treatment and long-term outcome in adult patients with Moyamoya disease in China. Cerebrovasc Dis 34:305–313
Fukui M (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (‘moyamoya’ disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 99(Suppl 2):S238–S240
Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases (2012) Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo) 52:245–266
Ishikawa T, Houkin K, Kamiyama H, Abe H (1997) Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease. Stroke 28:1170–1173
Starke RM, Komotar RJ, Connolly ES (2009) Optimal surgical treatment for moyamoya disease in adults: direct versus indirect bypass. Neurosurg Focus 26:E8
Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW (2017) Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg 5:1–7
Guey S, Tournier-Lasserve E, Hervé D, Kossorotoff M (2015) Moyamoya disease and syndromes: from genetics to clinical management. Appl Clin Genet 8:49–68
Acker G, Goerdes S, Schneider UC, Schmiedek P, Czabanka M, Vajkoczy P (2015) Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians. Eur J Neurol 22:1012–1017
Kraemer M, Heienbrok W, Berlit P (2008) Moyamoya disease in Europeans. Stroke 39:3193–3200
Krischek B, Kasuya H, Khan N, Tatagiba M, Roder C, Kraemer M (2011) Genetic and clinical characteristics of Moyamoya disease in Europeans. Acta Neurochir Suppl 112:31–34
Saarela M, Mustanoja S, Pekkola J, Tyni T, Hernesniemi J, Kivipelto L, Tatlisumak T (2017) Moyamoya vasculopathy - patient demographics and characteristics in the Finnish population. Int J Stroke 12:90–95
Suzuki J, Takaku A (1969) Cerebrovascular ‘moyamoya’ disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20:288–299
Czabanka M, Peña-Tapia P, Schubert GA, Heppner FL, Martus P, Horn P, Schmiedek P, Vajkoczy P (2011) Proposal for a new grading of Moyamoya disease in adult patients. Cerebrovasc Dis 32:41–50
Chung JW, Kim SJ, Bang OY, Kim KH, Ki CS, Jeon P, Yeon JY, Kim JS, Hong SC, Shin HJ (2016) Determinants of basal collaterals in moyamoya disease: clinical and genetic factors. Eur Neurol 75:178–185
Strother MK, Anderson MD, Singer RJ, Du L, Moore RD, Shyr Y, Ladner TR, Arteaga D, Day MA, Clemmons PF, Donahue MJ (2014) Cerebrovascular collaterals correlate with disease severity in adult North American patients with Moyamoya disease. AJNR Am J Neuroradiol 35:1318–1324
Silvestrini M, Troisi E, Matteis M, Cupini LM, Bernardi G (1996) Effect of smoking on cerebrovascular reactivity. J Cereb Blood Flow Metab 16:746–749
Markus HS, Harrison MJ (1992) Estimation of cerebrovascular reactivity using transcranial Doppler, including the use of breath-holding as the vasodilatatory stimulus. Stroke 23:668–673
Corsini E, Ciusani E, Gaviani P, Silvani A, Canazza A, Bernardi G, Calatozzolo C, DiMeco F, Meco FD, Salmaggi A (2012) Decrease in circulating endothelial progenitor cells in treated glioma patients. J Neuro-Oncol 108:123–129
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967
Kainth D, Chaudhry SA, Kainth H, Suri FK, Qureshi AI (2013) Epidemiological and clinical features of moyamoya disease in the USA. Neuroepidemiology 40(4):282–287
Bower RS, Mallory GW, Nwojo M, Kudva YC, Flemming KD, Meyer FB (2013) Moyamoya disease in a primarily white, midwestern US population: increased prevalence of autoimmune disease. Stroke 44(7):1997–1999
Hoshino H, Izawa Y, Suzuki N (2012) Research committee on Moyamoya disease. Epidemiological features of moyamoya disease in Japan. Neurol Med Chir (Tokyo) 52(5):295–298
Jang DK, Lee KS, Rha HK, Huh PW, Yang JH, Park IS, Ahn JG, Sung JH, Han YM (2014) Clinical and angiographic features and stroke types in adult moyamoya disease. AJNR Am J Neuroradiol 35(6):1124–1131
Kuroda S, Houkin K (2008) Moyamoya disease: current concepts and future perspectives. Lancet Neurol 7:1056–1066
Ganesan V, Smith ER (2015) Moyamoya: defining current knowledge gaps. Dev Med Child Neurol 57:786–787
Liu W, Senevirathna ST, Hitomi T, Kobayashi H, Roder C, Herzig R, Kraemer M, Voormolen MH, Cahová P, Krischek B, Koizumi A (2013) Genomewide association study identifies no major founder variant in Caucasian moyamoya disease. J Genet 92:605–609
Guey S, Kraemer M, Hervé D, Ludwig T, Kossorotoff M, Bergametti F, Schwitalla JC, Choi S, Broseus L, Callebaut I, Genin E, Tournier-Lasserve E, FREX consortium (2017) Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians. Eur J Hum Genet 25:995–1003
Miskinyte S, Butler MG, Hervé D, Sarret C, Nicolino M, Petralia JD, Bergametti F, Arnould M, Pham VN, Gore AV, Spengos K, Gazal S, Woimant F, Steinberg GK, Weinstein BM, Tournier-Lasserve E (2011) Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am J Hum Genet 88:718–728
Hervé D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S, Bergametti F, Essongue A, Berrou E, Krivosic V, Sainte-Rose C, Houdart E, Adam F, Billiemaz K, Lebret M, Roman S, Passemard S, Boulday G, Delaforge A, Guey S, Dray X, Chabriat H, Brouckaert P, Bryckaert M, Tournier-Lasserve E (2014) Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet 94:385–394
Blecharz KG, Frey D, Schenkel T, Prinz V, Bedini G, Krug SM, Czabanka M, Wagner J, Fromm M, Bersano A, Vajkoczy P (2017) Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease. J Cereb Blood Flow Metab 37:1527–1539
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bersano, A., Bedini, G., Nava, S. et al. GEN-O-MA project: an Italian network studying clinical course and pathogenic pathways of moyamoya disease—study protocol and preliminary results. Neurol Sci 40, 561–570 (2019). https://doi.org/10.1007/s10072-018-3664-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-018-3664-z